Product Name :
MIV-150
Description:
MIV-150 is a nonnucleoside reverse transcriptase (NNRT) inhibitor, blocking HIV-1 and HIV-2 infections, with an EC50<1 nM against HIV-1/HIV-2MN.
CAS:
231957-54-3
Molecular Weight:
368.36
Formula:
C19H17FN4O3
Chemical Name:
1-(5-cyanopyridin-2-yl)-3-[(1S,2S)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea
Smiles :
CCC(=O)C1C=CC(F)=C([C@@H]2C[C@@H]2NC(=O)NC2C=CC(=CN=2)C#N)C=1O
InChiKey:
NKPHEWJJTGPRSL-OCCSQVGLSA-N
InChi :
InChI=1S/C19H17FN4O3/c1-2-15(25)11-4-5-13(20)17(18(11)26)12-7-14(12)23-19(27)24-16-6-3-10(8-21)9-22-16/h3-6,9,12,14,26H,2,7H2,1H3,(H2,22,23,24,27)/t12-,14+/m1/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
MIV-150 is a nonnucleoside reverse transcriptase (NNRT) inhibitor, blocking HIV-1 and HIV-2 infections, with an EC50Product information|CAS Number: 231957-54-3|Molecular Weight: 368.36|Formula: C19H17FN4O3|Chemical Name: 1-(5-cyanopyridin-2-yl)-3-[(1S,2S)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea|Smiles: CCC(=O)C1C=CC(F)=C([C@@H]2C[C@@H]2NC(=O)NC2C=CC(=CN=2)C#N)C=1O|InChiKey: NKPHEWJJTGPRSL-OCCSQVGLSA-N|InChi: InChI=1S/C19H17FN4O3/c1-2-15(25)11-4-5-13(20)17(18(11)26)12-7-14(12)23-19(27)24-16-6-3-10(8-21)9-22-16/h3-6,9,12,14,26H,2,7H2,1H3,(H2,22,23,24,27)/t12-,14+/m1/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.Sotigalimab Cancer |Shelf Life: ≥12 months if stored properly.Exendin-4 supplier |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.PMID:33183084 |Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|The activity of MIV-150 to protect target cells from infection is assayed using a syncytial assay. The EC50 of MIV-150 against HIV-1MN in CEM.SS cells is below 1 nM. These data are in agreement with the findings of Medivir. MIV-150 effectively inactivated free virus with an EC50 of 0.004 μg/mL (or 0.01 μM). It is demonstrated MIV-150 is highly effective against HIV and that the drug blocks viruses that are resistant to other marketed HIV antiretrovirals such as Nevirapine, Delavirdine, and Efavirenz. In addition, resistance to MIV-150 develops more slowly than to other anti-HIV drugs tested. For example, in vitro studies demonstrate that resistance development in the presence of nevirapine and delavirdine takes only 4 to 5 weeks compared with 45 weeks in the presence of MIV-150.|Products are for research use only. Not for human use.|